TPST - Tempest Therapeutics, Inc.

QQQ $ 623.00 nm (nm)

DIA $ 473.56 nm (nm)

SPY $ 678.01 nm (nm)

TLT $ 88.92 nm (nm)

GLD $ 366.01 nm (nm)

Previous Close

$ 9.95

Open

$ 9.15

Bid

$ 10.00 x 12

Ask

$ 10.05 x 1

Day's Range

$ 9.15 - $ 10.07

52 Week Range

$ 5.35 - $ 15.08

Volume

42,210

Average Volume

Market Cap

44.18M

Beta (5Y Monthly)

$ 2.60

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-05-2025	09-30-2025	10-Q
2	08-11-2025	06-30-2025	10-Q
3	05-13-2025	03-31-2025	10-Q
4	03-27-2025	12-31-2024	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-08-2024	06-30-2024	10-Q
7	05-09-2024	03-31-2024	10-Q
8	03-19-2024	12-31-2023	10-K
9	11-08-2023	09-30-2023	10-Q
10	08-10-2023	06-30-2023	10-Q
11	05-10-2023	03-31-2023	10-Q
12	03-22-2023	12-31-2022	10-K
13	11-08-2022	09-30-2022	10-Q
14	08-15-2022	06-30-2022	10-Q
15	05-13-2022	03-31-2022	10-Q
16	03-29-2022	12-31-2021	10-K
17	11-10-2021	09-30-2021	10-Q
18	08-12-2021	06-30-2021	10-Q
19	05-13-2021	03-31-2021	10-Q
20	03-29-2021	12-31-2020	10-K
21	11-09-2020	09-30-2020	10-Q
22	08-10-2020	06-30-2020	10-Q
23	05-08-2020	03-31-2020	10-Q
24	03-11-2020	12-31-2019	10-K
25	11-13-2019	09-30-2019	10-Q
26	08-12-2019	06-30-2019	10-Q
27	05-15-2019	03-31-2019	10-Q
28	04-01-2019	12-31-2018	10-K
29	11-09-2018	09-30-2018	10-Q
30	08-09-2018	06-30-2018	10-Q
31	05-03-2018	03-31-2018	10-Q
32	03-15-2018	12-31-2017	10-K
33	11-02-2017	09-30-2017	10-Q
34	08-03-2017	06-30-2017	10-Q
35	05-09-2017	03-31-2017	10-Q
36	03-02-2017	12-31-2016	10-K
37	11-03-2016	09-30-2016	10-Q
38	08-04-2016	06-30-2016	10-Q
39	05-05-2016	03-31-2016	10-Q
40	02-26-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Tempest Therapeutics Q3 EPS $(0.79) Beats ...
11/05/2025 13:34:07

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of ...

12 Health Care Stocks Moving In Friday's A...
10/17/2025 21:07:13

12 Health Care Stocks Moving In Thursday's...
09/04/2025 21:13:45

Tempest Therapeutics Q2 EPS $(2.07) Beats ...
08/11/2025 20:22:58

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(2.07) per share which beat the analyst consensus estimate of ...

Tempest Announces $4.6M Registered Direct ...
06/11/2025 12:11:03

12 Health Care Stocks Moving In Wednesday'...
06/11/2025 12:07:40

why-circle-internet-group-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket

Why Circle Internet Group Shares Are Tradi...
06/09/2025 12:46:39

12 Health Care Stocks Moving In Monday's P...
06/09/2025 12:08:42

Tempest Announces It Has Received Orphan D...
06/05/2025 12:08:01

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscor...

Tempest Therapeutics Q1 EPS $(3.16) Beats ...
05/13/2025 20:45:29

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(3.16) per share which beat the analyst consensus estimate of ...

Tempest Presents New Amezalpat MOA Data Su...
04/28/2025 20:07:01

Tempest Receives FDA Orphan Drug Designati...
04/21/2025 12:01:19

tempest-weighs-ma-analyst-sees-a-broken-story-despite-phase-2-liver-cancer-study-success

Tempest Weighs M&A, Analyst Sees A "Broken...
04/10/2025 16:00:40

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cance...

Correction : Scotiabank Downgrades Tempest...
04/10/2025 12:27:25

Correction: Scotiabank analyst George Farmer downgrades Tempest Therapeutics (NASDAQ:TPST) from Sector Outperform to Sector Per...

HC Wainwright & Co. Downgrades Tempest The...
04/10/2025 10:48:04

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:TPST) from Buy to Neutral and maint...

Tempest Therapeutics Plans to Explore Stra...
04/09/2025 20:35:18

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carci...

Trading Halt: Halt status updated at 8:55:...
04/09/2025 12:55:04

Trading Halt: Halted at 7:50:00 p.m. ET - ...
04/08/2025 23:50:04

Scotiabank Maintains Sector Outperform on ...
03/28/2025 14:36:33

Scotiabank analyst George Farmer maintains Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform and lowers the price ...

HC Wainwright & Co. Maintains Buy on Tempe...
03/28/2025 11:35:29

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the pric...